



LTT regarding the use of the AstraZeneca COVID-19 vaccine in Denmark

- The Danish Medicines Agency and the Danish Health Authority agrees with EMA that the AstraZeneca vaccine is effective and supports EMA's general assessment that the benefits of the vaccine outweigh the risks.
- The current epidemiological situation in Denmark is at a relatively stable point. The majority of persons at risk have been vaccinated or are scheduled to be vaccinated. In this light, the Danish Health Authority has decided not to bring back the AstraZeneca COVID-19 vaccine in the Danish national vaccine roll-out in the current situation.
- In its decision, the Danish Health Authority has weighed the current epidemiological situation in Denmark against the specific risk profile of the vaccine.
- It is a decision taken regarding a concrete vaccine in a concrete epidemiological situation. Had the situation in Denmark been different, the decision not to utilize the specific vaccine could have been different.
- The AstraZeneca vaccine will still be approved for use in Denmark and the contract with AstraZeneca will continue. The Danish Health Authority has not ruled out that the vaccine could be resumed in the Danish national vaccination programme if the situation changes.
- We stand ready to provide additional information.